+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Coccidioidomycosis Market by End User (Ambulatory Centers, Clinics, Hospitals), Drug Class (Azoles, Echinocandins, Polyenes), Distribution Channel, Infection Type, Route Of Administration - Global Forecast 2025-2030- Product Image
Coccidioidomycosis Market by End User (Ambulatory Centers, Clinics, Hospitals), Drug Class (Azoles, Echinocandins, Polyenes), Distribution Channel, Infection Type, Route Of Administration - Global Forecast 2025-2030- Product Image
New

Coccidioidomycosis Market by End User (Ambulatory Centers, Clinics, Hospitals), Drug Class (Azoles, Echinocandins, Polyenes), Distribution Channel, Infection Type, Route Of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6116645
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Coccidioidomycosis, a fungal infection endemic to certain arid regions, has emerged as a focal point for healthcare providers and researchers alike. Known commonly as Valley fever, the disease exhibits a complex clinical profile, ranging from mild, self-limiting respiratory symptoms to severe disseminated forms that challenge current therapeutic protocols. Moreover, rising awareness among clinicians and patients has driven heightened demand for rapid and accurate diagnostic tools, underscoring the critical role of early detection in improving patient outcomes.

As the landscape evolves, interdisciplinary collaboration between epidemiologists, mycologists, and pharmaceutical developers has become indispensable. Consequently, a holistic understanding of disease prevalence, risk factors, and patient demographics is essential for crafting effective intervention strategies. Furthermore, regulatory frameworks and reimbursement policies have begun to reflect the urgent need for advanced antifungal agents, setting the stage for a dynamic interplay between innovation and market access. This introduction establishes the foundation for exploring transformative trends, regulatory dynamics, and strategic imperatives that shape the coccidioidomycosis domain.

Unveiling Transformative Shifts Reshaping the Coccidioidomycosis Treatment Landscape Driven by Technological Advances and Patient-Centric Innovations

Recent years have witnessed transformative shifts that are redefining the coccidioidomycosis landscape across research, diagnostics, and patient care. Technological advancements in molecular assays and point-of-care testing have dramatically reduced turnaround times for pathogen identification. Accordingly, clinicians can initiate targeted therapies sooner, which has meaningful implications for disease progression and patient quality of life. Moreover, digital health platforms and telemedicine services have expanded remote monitoring capabilities, allowing for continuous patient engagement and adherence support.

In parallel, novel drug delivery systems, such as nanoparticle-based formulations and extended-release oral suspensions, are gaining traction. This evolution addresses historical limitations related to drug toxicity and dosing frequency. Furthermore, patient advocacy groups have amplified the voice of those affected, driving greater investment in patient-centric research initiatives. As a result, partnerships between industry stakeholders and academic centers have intensified, fostering a more collaborative environment for clinical trial design and real-world evidence generation. These converging forces are collectively reshaping the therapeutic paradigm and creating new pathways to improved patient outcomes.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Antifungal Drug Supply Chains, Pricing Structures, and Access to Care

The introduction of revised tariff structures by the United States in 2025 has imposed a series of upstream and downstream effects on the supply chains servicing antifungal therapies. Initially, increased import duties on active pharmaceutical ingredients have elevated production costs, prompting manufacturers to reassess sourcing strategies and in some cases to localize certain manufacturing processes closer to end markets. Consequently, stakeholders must navigate evolving trade policies while maintaining continuity of supply for critical therapeutics.

Furthermore, distributors and logistics providers have adapted to these changes by renegotiating contractual terms and optimizing channel routing to mitigate cost pressures. This strategic realignment has influenced pricing structures at the point of care, requiring payers and providers to absorb or offset incremental expenses. In response, collaborative dialogue between government agencies and industry leaders has intensified, fostering policy forums aimed at striking a balance between trade protectionism and patient access. As the market adjusts to these new regulatory conditions, resilience and agility in operational planning have become paramount for preserving both affordability and availability of life-saving antifungal drugs.

Deep Dive into Segmentation Insights Illuminating End Users, Drug Classes, Distribution Channels, Infection Types, and Administration Routes

A nuanced understanding of market segmentation illuminates the diverse pathways through which coccidioidomycosis interventions reach patients. The end user dimension encompasses ambulatory centers, which include both day care and outpatient facilities, general clinics alongside specialized infectious disease and pulmonology clinics, as well as secondary and tertiary care hospitals. Research institutes further split into government and private establishments, each contributing unique insights through clinical studies and translational research. Transitioning to drug class segmentation, agents fall into the azole category-spanning fluconazole, itraconazole, and voriconazole-the echinocandin class represented by caspofungin and micafungin, and the polyene amphotericin B, each with distinct safety and efficacy profiles.

Distribution channels trace the flow of products from hospital pharmacies operating inpatient and outpatient dispensaries through prescription portals, telemedicine platforms, and retail outlets managed by both chain and independent operators. Infection type segmentation distinguishes acute presentations, those that assume a chronic course, and cases where the pathogen disseminates beyond primary sites. Finally, route of administration analysis highlights intravenous therapies available in both conventional and liposomal formats alongside oral suspensions and tablets. Together, these segmentation lenses offer a comprehensive framework for tailoring market strategies to specific clinical contexts, patient needs, and stakeholder requirements.

Uncovering Regional Variations in Coccidioidomycosis Dynamics Across Americas, Europe Middle East and Africa, and Asia Pacific Markets

Regional dynamics play a critical role in shaping the epidemiology and management of coccidioidomycosis across different territories. In the Americas, variations in environmental exposure, healthcare infrastructure, and public health initiatives drive a multifaceted response to disease detection and treatment. Surveillance networks and awareness campaigns are particularly strong in endemic zones, fostering collaboration between public and private entities to enhance diagnostic capabilities and patient education.

Across Europe, the Middle East, and Africa, the convergence of migratory patterns, climate variability, and evolving regulatory landscapes has heightened attention to coccidioidomycosis. While some regions benefit from advanced laboratory networks and reimbursement frameworks, others face resource constraints that underscore the importance of cost-effective diagnostic tools and scalable therapeutic solutions. Meanwhile, in the Asia-Pacific area, emerging clinical centers of excellence are pioneering research into novel antifungal modalities, supported by increasing investments in healthcare modernization and digital health integration. These regional distinctions underscore the necessity of tailored strategies that align product development and market access plans with localized patient needs and regulatory requirements.

Analyzing Leading Stakeholders and Pharmaceutical Innovators Driving Advances in Coccidioidomycosis Prevention Diagnosis and Therapeutics

Leading pharmaceutical companies and innovative biotech firms have emerged at the forefront of the coccidioidomycosis arena, each contributing unique strengths to prevention, diagnosis, and treatment strategies. Major players have expanded their azole pipelines through incremental molecule improvements, while certain specialized research organizations focus on next-generation echinocandin analogs that promise enhanced tolerability. Concurrently, advances in liposomal formulations of amphotericin have been driven by collaborations between formulation scientists and contract development partners.

Diagnostic innovators have introduced highly sensitive assay platforms that reduce the burden of invasive procedures, leveraging both laboratory instrumentation and point-of-care devices. In parallel, strategic alliances between contract research organizations and academic centers have facilitated robust real-world evidence generation, accelerating regulatory filings. Furthermore, several emerging companies are pioneering companion diagnostics that enable personalized antifungal therapy, thereby optimizing clinical outcomes and minimizing adverse events. This interplay between established multinational corporations and nimble biotech ventures continues to fuel innovation and drive competitive differentiation in the coccidioidomycosis ecosystem.

Strategic and Practical Recommendations Empowering Industry Leaders to Navigate and Innovate in the Evolving Coccidioidomycosis Treatment Environment

To capitalize on the shifting dynamics of the coccidioidomycosis landscape, industry leaders should prioritize the diversification of supply chains to reduce vulnerability to tariff fluctuations and logistical disruptions. Establishing regional manufacturing hubs and fostering strategic partnerships with local contract developers can enhance resilience and ensure continuity of supply. Moreover, investment in rapid molecular diagnostics and digital health platforms will drive earlier detection, improve patient adherence, and support data-driven decision-making across care pathways.

In addition, stakeholders are advised to engage closely with regulatory authorities to streamline approval pathways for novel antifungal agents and companion diagnostics. This can be achieved through transparent data sharing, alignment on trial end points, and the adoption of regulatory science initiatives. Finally, incorporating patient-centric design principles into clinical development strategies-such as adaptive dosing regimens and simplified administration formats-will differentiate product offerings and foster stronger engagement with advocacy groups. By implementing these recommendations, decision-makers can navigate current challenges and position their organizations for sustainable growth in the evolving market.

Comprehensive Research Methodology Detailing Expert Consultations Data Triangulation and Rigorous Quality Assurance for Market Analysis

This research employs a rigorous methodology combining comprehensive secondary research, expert interviews with clinicians and mycology specialists, and a detailed review of regulatory filings. Initial desk research encompassed literature surveys, clinical trial registries, and peer-reviewed publications to establish a foundational understanding of disease burden, treatment paradigms, and technological advances. Insights from industry veterans and key opinion leaders were then systematically integrated through structured interviews to validate findings and uncover emerging trends.

Data triangulation techniques were applied to reconcile disparate sources and ensure consistency across clinical, commercial, and regulatory dimensions. Quantitative and qualitative inputs were rigorously vetted through a multi-layered quality-assurance process, incorporating internal reviews and senior advisory oversight. This comprehensive approach guarantees that the market analysis not only reflects current realities but also anticipates potential inflection points, thereby equipping stakeholders with actionable intelligence grounded in robust evidence.

Holistic Conclusion Summarizing Key Insights Opportunities and Next Steps for Stakeholders in the Coccidioidomycosis Ecosystem

The journey through epidemiology, tariff impacts, segmentation, regional dynamics, and stakeholder activities has underscored the intricate nature of the coccidioidomycosis ecosystem. Holistically, advancements in diagnostic technologies and drug formulation are converging to address long-standing clinical challenges, while evolving trade policies have prompted a renewed focus on supply chain resilience. Segmentation analysis highlights the importance of tailored strategies for distinct end users, drug classes, and therapeutic contexts, and regional insights reveal that a one-size-fits-all approach is no longer viable.

As the competitive landscape intensifies, collaboration across public health authorities, industry innovators, and patient communities will be vital to sustaining momentum. By aligning development priorities with evolving regulatory frameworks and patient expectations, stakeholders can unlock new avenues for therapeutic impact and commercial success. Ultimately, the insights presented here form a cohesive narrative that equips decision-makers to navigate complexity, seize emerging opportunities, and drive meaningful improvements in the management of coccidioidomycosis.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • End User
    • Ambulatory Centers
      • Day Care Centers
      • Outpatient Centers
    • Clinics
      • General Clinics
      • Infectious Disease Clinics
      • Pulmonology Clinics
    • Hospitals
      • Secondary Care Hospitals
      • Tertiary Care Hospitals
    • Research Institutes
      • Government Research Institutes
      • Private Research Institutes
  • Drug Class
    • Azoles
      • Fluconazole
      • Itraconazole
      • Voriconazole
    • Echinocandins
      • Caspofungin
      • Micafungin
    • Polyenes
      • Amphotericin B
  • Distribution Channel
    • Hospital Pharmacy
      • Inpatient Pharmacy
      • Outpatient Pharmacy
    • Online Pharmacy
      • Prescription Portals
      • Telemedicine Platforms
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • Infection Type
    • Acute
    • Chronic
    • Disseminated
  • Route Of Administration
    • Intravenous
      • Conventional Formulations
      • Liposomal Formulations
    • Oral
      • Suspensions
      • Tablets
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • Abbott Laboratories
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Meridian Bioscience, Inc.
  • ImmunoMycologics, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing incidence of coccidioidomycosis driven by climate change and population migration
5.2. Advancement of novel antifungal agents in late stage clinical trials for valley fever
5.3. Integration of rapid point of care diagnostic platforms to improve early detection
5.4. Progress in vaccine development pipelines amid increasing private and public funding
5.5. Municipal healthcare policy revisions affecting disease management reimbursement and coverage
5.6. Expansion of telemedicine services to support remote monitoring of coccidioidomycosis patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Coccidioidomycosis Market, by End User
8.1. Introduction
8.2. Ambulatory Centers
8.2.1. Day Care Centers
8.2.2. Outpatient Centers
8.3. Clinics
8.3.1. General Clinics
8.3.2. Infectious Disease Clinics
8.3.3. Pulmonology Clinics
8.4. Hospitals
8.4.1. Secondary Care Hospitals
8.4.2. Tertiary Care Hospitals
8.5. Research Institutes
8.5.1. Government Research Institutes
8.5.2. Private Research Institutes
9. Coccidioidomycosis Market, by Drug Class
9.1. Introduction
9.2. Azoles
9.2.1. Fluconazole
9.2.2. Itraconazole
9.2.3. Voriconazole
9.3. Echinocandins
9.3.1. Caspofungin
9.3.2. Micafungin
9.4. Polyenes
9.4.1. Amphotericin B
10. Coccidioidomycosis Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.2.1. Inpatient Pharmacy
10.2.2. Outpatient Pharmacy
10.3. Online Pharmacy
10.3.1. Prescription Portals
10.3.2. Telemedicine Platforms
10.4. Retail Pharmacy
10.4.1. Chain Pharmacy
10.4.2. Independent Pharmacy
11. Coccidioidomycosis Market, by Infection Type
11.1. Introduction
11.2. Acute
11.3. Chronic
11.4. Disseminated
12. Coccidioidomycosis Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.2.1. Conventional Formulations
12.2.2. Liposomal Formulations
12.3. Oral
12.3.1. Suspensions
12.3.2. Tablets
13. Americas Coccidioidomycosis Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Coccidioidomycosis Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Coccidioidomycosis Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Quest Diagnostics Incorporated
16.3.2. Laboratory Corporation of America Holdings
16.3.3. Thermo Fisher Scientific Inc.
16.3.4. F. Hoffmann-La Roche Ltd
16.3.5. Danaher Corporation
16.3.6. Abbott Laboratories
16.3.7. bioMérieux SA
16.3.8. Bio-Rad Laboratories, Inc.
16.3.9. Meridian Bioscience, Inc.
16.3.10. ImmunoMycologics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. COCCIDIOIDOMYCOSIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. COCCIDIOIDOMYCOSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. COCCIDIOIDOMYCOSIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. COCCIDIOIDOMYCOSIS MARKET: RESEARCHAI
FIGURE 26. COCCIDIOIDOMYCOSIS MARKET: RESEARCHSTATISTICS
FIGURE 27. COCCIDIOIDOMYCOSIS MARKET: RESEARCHCONTACTS
FIGURE 28. COCCIDIOIDOMYCOSIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. COCCIDIOIDOMYCOSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DAY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DAY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTIOUS DISEASE CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTIOUS DISEASE CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PULMONOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PULMONOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CASPOFUNGIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CASPOFUNGIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY MICAFUNGIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY MICAFUNGIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PRESCRIPTION PORTALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PRESCRIPTION PORTALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY TELEMEDICINE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY TELEMEDICINE PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ACUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CONVENTIONAL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CONVENTIONAL FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES COCCIDIOIDOMYCOSIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 195. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2018-2024 (USD MILLION)
TABLE 198. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2025-2030 (USD MILLION)
TABLE 199. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 200. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 201. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 202. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 203. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 204. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 205. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 206. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 207. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 208. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 209. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
TABLE 210. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2030 (USD MILLION)
TABLE 211. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 212. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 213. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 216. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 217. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 218. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 219. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 220. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 221. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 222. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 223. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 226. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 227. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 228. CANADA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 229. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2018-2024 (USD MILLION)
TABLE 232. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2025-2030 (USD MILLION)
TABLE 233. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 234. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 235. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 236. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 237. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 238. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 239. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 242. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 243. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
TABLE 244. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2030 (USD MILLION)
TABLE 245. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 246. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 247. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 250. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 251. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 252. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 253. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 254. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 255. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 256. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 257. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 260. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 261. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 262. MEXICO COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 309. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 310. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 311. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
TABLE 312. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2030 (USD MILLION)
TABLE 313. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 314. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 315. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 318. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 319. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 320. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 321. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 322. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 323. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
TABLE 324. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
TABLE 325. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 328. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 329. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 330. ARGENTINA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 331. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 332. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 333. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2018-2024 (USD MILLION)
TABLE 334. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AMBULATORY CENTERS, 2025-2030 (USD MILLION)
TABLE 335. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 336. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 337. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 338. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 339. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 340. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 341. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD M

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Coccidioidomycosis market report include:
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • Abbott Laboratories
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Meridian Bioscience, Inc.
  • ImmunoMycologics, Inc.

Related Topics

Related Reports

Coccidioidomycosis Drug Global Market Report 2025 - Product Image

Coccidioidomycosis Drug Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Coccidioidomycosis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Coccidioidomycosis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 72 Pages
  • Global
From
Coccidioidomycosis - Pipeline Insight, 2025 - Product Image

Coccidioidomycosis - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Valley Fever Market Report 2025 - Product Image

Valley Fever Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Cryptococcosis Market by Drug Class (Azoles, Echinocandins, Polyenes), Indication (Cryptococcal Meningitis, Disseminated Cryptococcosis, Pulmonary Cryptococcosis), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Cryptococcosis Market by Drug Class (Azoles, Echinocandins, Polyenes), Indication (Cryptococcal Meningitis, Disseminated Cryptococcosis, Pulmonary Cryptococcosis), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.